VANCOUVER, British Columbia, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (the "Company" or "Treatment") is pleased to announce that it is rebranding and reincorporating as Rocket Doctor AI Inc. This milestone reflects the Company's continued evolution and its commitment to advancing its strategic vision. Concurrently with the completion of the proposed name change, the Company's trading symbol on the Canadian Securities Exchange will be changed from "TRUE" ...

Core Insights - PAVmed Inc. has provided a business update highlighting its financial results and developments within its subsidiaries, Lucid Diagnostics and Veris Health, for the second quarter of 2025 [1][4] Financial Performance - Lucid Diagnostics recognized $1.2 million in revenue from 2,756 EsoGuard® tests processed in Q2 2025 [7] - The company strengthened its balance sheet with a public offering that netted approximately $16.1 million, extending its financial runway into 2026 [7] - PAVmed reported a net loss attributable to common stockholders of approximately $13.3 million for the three months ended June 30, 2025, translating to a loss of $(0.74) per diluted share [10] Business Developments - Lucid initiated patient testing under a new commercial insurance coverage policy from Highmark Blue Cross Blue Shield, effective May 26, 2025 [7] - Veris Health completed a $2.5 million direct equity financing, allowing it to fund the development of its implantable physiological monitor through FDA clearance [7] - Veris is advancing towards regulatory clearance for its implantable monitor and is integrating with The Ohio State's James Cancer Hospital for commercial deployment [7] Strategic Partnerships and Initiatives - PAVmed is actively evaluating new opportunities to leverage its platform and diversify its portfolio, including discussions with academic medical centers [7] - Lucid partnered with Hoag to launch a comprehensive EsoGuard esophageal precancer testing program [7] Conference Call Information - A conference call and webcast were scheduled for August 14, 2025, to discuss the business update and financial results [2][3]

Core Insights - Hims & Hers Health, Inc. (HIMS) has faced short-term stock losses, declining 21.3% while the industry rose by 1.7% [1] - The company reported strong second-quarter 2025 results, with significant growth in subscribers and online revenue [2][9] - HIMS anticipates third-quarter 2025 revenues between $570 million and $590 million, reflecting a year-over-year increase of 42-47% [7] Financial Performance - HIMS experienced a 30.8% growth in subscribers, reaching 2.4 million, and a 29.8% increase in monthly online revenue per subscriber to $74 [10] - The gross margin contracted by 491 basis points due to rising product costs, which is a concern for future profitability [9][15] - The company’s revenue guidance for the full year 2025 is set at $2.3 billion to $2.4 billion, with an EBITDA outlook of $295 million to $335 million [11] Strategic Developments - HIMS completed an $870 million convertible senior notes offering to support global expansion and AI-led innovation [12] - The company plans to launch a weight loss program in Canada in 2026, aiming to capture market share in an underserved segment [13] - HIMS acquired ZAVA, a European digital health platform, enhancing its geographic reach and service offerings [14] Market Position - HIMS' forward 12-month price-to-sales (P/S) ratio is 4X, lower than the industry average of 5.5X but higher than its three-year median of 2.3X [16] - Estimates for HIMS' 2025 earnings have decreased by 12.3% to 64 cents in the past 60 days [19] - The company maintains a favorable growth outlook, supported by a strong business model and financial stability [22]

Financial Data and Key Metrics Changes - Total revenues for Q2 2025 were $5.4 million, down from $6.3 million in Q2 2024 and $6.8 million in Q1 2025, reflecting a decline due to the non-renewal of a large national health plan and a strategic shift towards a SaaS-like revenue model [29][30] - GAAP gross margin increased to 65% from 44% year over year, while non-GAAP gross margin was maintained at around 80% in the core B2B2C channel [10][30] - Operating expenses were reduced by 36% to $12.2 million from $18.9 million in Q2 2024, resulting in a narrowed operating loss of $9.2 million, down from $16.2 million [30] Business Line Data and Key Metrics Changes - The company signed 21 new clients year-to-date, with 80% of these accounts focused on multi-condition programs, aligning with the company's strategy [8][12] - Committed annual recurring revenue (CARR) increased by $5 million, with a pipeline totaling $53 million, indicating strong future revenue potential [9][17] - The B2B2C business continues to operate at over 80% gross margins on a non-GAAP basis, demonstrating the efficiency of the business model [10][30] Market Data and Key Metrics Changes - The company serves over 100 clients, including four national health plans and six regional health plans, indicating a diversified client base [13] - The pipeline includes more than 25 qualified health plans for 2026, a significant increase from three health plans in the pipeline a year ago [19] - The company is expanding into the $150 billion sleep health market through a partnership, which is expected to enhance its multi-condition model [21] Company Strategy and Development Direction - The company is focusing on sustainable annual recurring revenue (ARR) growth, emphasizing the importance of differentiated solutions and disciplined execution [12] - The strategy includes leveraging AI to enhance operational efficiency and member engagement, which is expected to reduce operating expenses by 15% over the next year [36] - The company aims to build a scalable financial profile with a clear pathway to cash flow positivity, focusing on high-margin, recurring revenues [32][36] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that Q2 revenues were below expectations due to short-term headwinds but expressed confidence in the company's growth trajectory and the quality of new client acquisitions [7][8] - The company is optimistic about closing the revenue gap and accelerating growth, supported by strong metrics in client quality and recurring revenues [10][11] - Management highlighted the importance of AI in driving future growth and operational efficiency, positioning the company as a leader in the digital health space [36] Other Important Information - The company has undergone a full review of its channel partner network, resulting in revitalized partnerships and a stronger value proposition [15] - The company is transitioning from one-time revenues to recurring revenues, which is expected to enhance long-term financial stability [20] - The company ended Q2 2025 with $22.1 million in cash and short-term deposits, bolstered by recent debt restructuring [30] Q&A Session Summary Question: Was there any churn that contributed to the revenue decline in Q2? - Management confirmed that there was no churn in annual recurring revenue, attributing the decline primarily to the non-renewal of a large health plan contract [39][40] Question: Can you provide more details on the services that the health plan decided to discontinue? - The health plan discontinued a Medicaid maternity program, opting to insource it, which was not a reflection of the company's performance [42][43] Question: What differentiates the current health plan reductions from future wins? - Management clarified that the non-renewal was an isolated incident and emphasized the diversification of their client base, with new significant accounts being signed [46][48] Question: Can you elaborate on the restructuring of the partnership program? - The company is focusing on strategic partnerships to enhance service offerings without expanding internal capabilities, particularly in areas like sleep health [49][50] Question: What are the expectations for operating expenses in the next 12 to 15 months? - Management anticipates a 15% reduction in operating expenses, aiming for quarterly expenses to be around $8 million by the end of next year [52][53] Question: What benefits does the claims-based billing infrastructure provide? - The addition of claims-based billing allows the company to tap into a larger profit pool by rendering services as claims, which is a significant shift from the current administrative budget billing [58][60]

Core Insights - DarioHealth Corp. reported second quarter 2025 revenue of $5.4 million, down from $6.3 million in Q2 2024 and $6.8 million in Q1 2025, primarily due to a shift in scope with a large national health plan client that was not renewed [1][10][12] - The company is focusing on signing new B2B2C clients to drive sustainable annual recurring revenue (ARR) growth, rather than relying on one-time revenues, which contributed to the revenue decline [2][3] - DarioHealth has adjusted its cash flow breakeven estimates to late 2026 to early 2027, reflecting slower onboarding and revenue recognition from new clients [2][3] Financial Performance - Revenue for Q2 2025 was $5.4 million, a decrease of 14% year-over-year and 20% quarter-over-quarter [10][12] - Gross profit for Q2 2025 was $3.0 million, an increase of 8% year-over-year, with a gross margin of 55%, up from 44% in Q2 2024 [11][12] - Operating loss narrowed by 43% year-over-year to $9.2 million in Q2 2025, with operating expenses decreasing by 36% to $12.2 million [15][24] Strategic Developments - The company signed 21 new clients year-to-date, including a top U.S. healthcare institution and two regional health plans, and is on track to achieve a total of 40 new clients by the end of 2025 [6][12] - DarioHealth is building a recurring revenue business with a strong pipeline of $53 million in commercial opportunities, with over $5 million in advanced stages towards ARR [5][12] - The company is enhancing its AI capabilities to drive operational efficiencies and improve patient engagement, expecting a 15% reduction in operating expenses over the next 12 to 15 months [9][12] Market Position and Future Outlook - DarioHealth is entering the $150 billion sleep apnea market through a partnership with GreenKey Health and has launched a GLP-1 + cardiometabolic solution deal with a national benefit administrator [12][24] - The company anticipates that two new health plan clients will represent multi-million-dollar opportunities, with a full-suite national health plan set to launch in the second half of 2025 [3][6] - DarioHealth's business model is designed for efficient scaling, supported by operational efficiencies and a focus on high-margin, multi-condition platform contracts [5][7]

Core Viewpoint - Scryb Inc. has provided an update regarding its holdings in Cybeats Technologies Corp, following a debt settlement transaction that involved the acquisition of common shares [1][2]. Group 1: Acquisition Details - On August 5, 2025, Scryb acquired 9,788,450 common shares of Cybeats in exchange for settling $978,845 of debt, as part of a larger transaction where Cybeats issued a total of 15,000,000 common shares to settle $1,500,000 of outstanding debt [2]. - The common shares acquired are subject to a hold period of four months and one day starting from the closing date of the transaction [2]. Group 2: Ownership Structure - Prior to the debt settlement, Scryb owned or controlled 64,643,500 common shares and 13,125,000 warrants, representing approximately 49.17% and 53.78% of the issued and outstanding common shares of Cybeats on an undiluted and partially diluted basis, respectively [4]. - After the debt settlement and accounting for other transactions, Scryb now owns or controls 74,431,950 common shares and 13,125,000 warrants, representing approximately 38.59% and 42.50% of the issued and outstanding common shares of Cybeats on an undiluted and partially diluted basis, respectively [5]. Group 3: Future Intentions - The acquisition of the securities was completed for investment purposes, and Scryb may adjust its ownership in Cybeats based on market conditions and other factors in the future [6].

Financial Data and Key Metrics Changes - Total members increased by 52% year over year to 752,000 [4][17] - Revenue rose by 49% year over year to $61 million [5][34] - GAAP gross margin improved to 66% from 60% year over year, while non-GAAP gross margin reached 68% [5][35] - GAAP net loss narrowed to $5 million compared to $11 million in Q2 2024 [5][39] - Adjusted EBITDA loss was $200,000, significantly improved from a $7 million loss in Q2 2024 [5][39] Business Line Data and Key Metrics Changes - Member growth was driven by strong sales of GLP-1 offerings and multi-condition adoption [17][34] - The GLP-1 CareTrack program showed significant growth, contributing to overall member increases [53][54] Market Data and Key Metrics Changes - The total addressable market is estimated to be over $135 billion, with only 14% penetration in self-insured lives and 1% in Medicare Advantage [13][22] - Existing health plan partners cover approximately 156 million lives, representing a significant growth opportunity [22][23] Company Strategy and Development Direction - The company focuses on a multi-condition platform rather than point solutions, which has become a key differentiator [20][31] - Innovation is a strategic pillar, with recent launches like Omada Spark, an AI agent for member support [24][28] - The company aims to leverage AI to enhance member engagement and operational efficiency [49][50] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing momentum and the potential for growth in the GLP-1 landscape [66][88] - The company is focused on balancing growth and profitability, with strategic investments planned for the second half of the year [66][67] Other Important Information - The company ended Q2 with cash and equivalents of $223 million, a significant increase from $59 million in Q1 2025 [40] - Total debt was $31 million, which was paid off after the quarter [41] Q&A Session Summary Question: How is technology being leveraged to scale the platform? - Management highlighted the integration of AI technologies to enhance member experience and care team efficiency, with positive early data on member engagement [44][48] Question: What is the current status of the GLP-1 CareTrack program? - The program is experiencing significant growth, although it still represents a minority of total membership [53][54] Question: What is driving member growth? - Growth is attributed to successful upselling, improved outreach productivity, and the effectiveness of multi-channel marketing [60][62] Question: How does the company balance growth and profitability? - The company plans to make targeted investments while maintaining a focus on profitability, especially in the GLP-1 and AI sectors [66][67] Question: What is the competitive landscape like? - The company sees strong engagement and clinical outcomes as key differentiators in a competitive market, with a focus on proactive care and clinical evidence [75][76]

Core Insights - Hims & Hers Health, Inc. (HIMS) is focusing on integrating technology platforms to enhance personalized healthcare delivery, highlighted by its acquisition of ZAVA, a European digital health provider, which facilitates cross-border platform integration [1][7] - The company is investing in personalization technologies, including upgrades to pharmacy infrastructure and lab testing integrations, to improve clinical accuracy in treatments [2][7] - Hims & Hers is transitioning from addressing single health concerns to enabling proactive health management through a fully integrated, tech-powered ecosystem [3] Company Expansion and Strategy - The acquisition of ZAVA allows Hims & Hers to offer 24/7 virtual care and centralized pharmacy fulfillment, expanding its geographic reach and service capabilities [1][7] - The planned expansion into Canada coincides with the market debut of semaglutide, showcasing the company's strategy of leveraging tech integration for timely market entries [2][7] Financial Performance - Hims & Hers shares have increased by 111.4% year to date, significantly outperforming the industry growth of 17.3% [6] - The Zacks Consensus Estimate for HIMS' 2025 earnings per share indicates a projected improvement of 151.9% from 2024 [8] Valuation Metrics - Hims & Hers has a forward 12-month price-to-sales (P/S) ratio of 4.3X, which is lower than the industry average of 5.5X but higher than its three-year median of 2.3X [10]

As Ontario's healthcare system evolves, Rocket Doctor remains focused on strengthening access, supporting physician-led care, and leveraging technology to meet the needs of patients, especially those in regions hit hardest by provider shortages and system gaps. 2024 marked the worst year on record for ER closures in Ontario, with 1 in 5 hospitals experiencing unplanned shutdowns, especially in rural areas. Ontario's family physician workforce is aging, with 15% of patients attached to doctors nearing retire ...

Core Insights - Profusa, Inc. has recently gone public on the Nasdaq under the ticker PFSA and is focused on advancing its personalized biochemistry technology platform for clinical applications [1][2] - The company has outlined a growth strategy based on five pillars: revenue growth and pipeline development, AI infrastructure, clinical and regulatory pathways, financial structure, and operational scaling [2] Revenue Growth and Pipeline Development - Profusa is on track to generate revenue from research use applications of its technology, which will enhance commercial operations and expand the capabilities of its platform [3] - Future personalized healthcare applications being pursued include lactate, carbon dioxide, sodium, and ethanol [3] Clinical and Regulatory Pathways - The company is progressing towards the European launch of its Lumee™ platform for tissue oxygen monitoring, with a target commercial launch in Q1 2026 [4] - The global addressable market for tissue oxygen monitoring is estimated at approximately $10 billion, with around 300,000 endovascular procedures occurring annually in Europe [4] Continuous Glucose Monitoring - Profusa's continuous glucose monitoring platform targets a global addressable market of over 500 million patients, with human validation data expected to be published soon [5] - Pivotal studies for this platform are anticipated to commence in late 2026, aiming for commercialization by mid-2027 [5] Financial Structure and Strategies - The company has secured a $100 million ELOC facility to support its growth phase and is implementing a strategic treasury plan focused on digital investment [6] - This financial strategy aims to enhance shareholder value and attract open market investors [6] Scale of Operations - Profusa is expanding its operational capabilities to prepare for scaling its business and executing its vision [7] Commitment to Innovation - The company is dedicated to delivering its technology to the clinical community, addressing the needs of patients with chronic diseases and contributing to personalized healthcare [8] - Profusa's management team is focused on achieving technological and financial milestones to enhance shareholder value [9]